Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, 980-8574, Japan.
Eur J Heart Fail. 2014 Mar;16(3):309-16. doi: 10.1002/ejhf.22. Epub 2013 Dec 31.
It is still controversial whether elevated baseline heart rate (HR) is associated with higher mortality in patients with heart failure (HF) with preserved ejection fraction (HFpEF). We compared the impacts of baseline HR on mortality in patients with HFpEF and those with HF with reduced ejection fraction (HFrEF).
We enrolled consecutive 2688 patients in Stage C or D HF with sinus rhythm from our Chronic Heart Failure Analysis and Registry in the Tohoku District 2 (CHART-2) Study (n = 10 219). The prognostic impact of HR increase was compared between the two groups, defined as left ventricular ejection fraction of < 50% (HFrEF) and > 50% (HFpEF). Cox regression analysis revealed that elevated baseline HR was associated with increased all-cause mortality in both groups [hazard ratio for the highest tertile (HH) 1.77 in HFrEF, P = 0.008; HH1.82 in HFpEF, P = 0.001]. However, as for mode of death, elevated HR was associated with cardiovascular (CV) death in HFpEF (HH 2.17, P = 0.012), but the association was modest in HFrEF (HH1.49, P = 0.14): in particular, impact on HF death was different between HFpEF (HH 3.79, P = 0.020) and HFrEF (HH 1.07, P = 0.864). In contrast, the prognostic impact of baseline HR on non-CV death was noted only in patients with HFrEF. β-Blocker therapy was associated with reduced HF mortality in HFrEF (hazard ratio 0.49, P = 0.038) but not in HFpEF (hazard ratio 0.64, P = 0.321).
Elevated HR was associated with increased CV death in HFpEF compared with HFrEF, although its impact on all-cause mortality was comparable between the two groups.
静息心率(HR)升高与射血分数保留的心力衰竭(HFpEF)患者的死亡率升高之间的关系仍存在争议。我们比较了基线 HR 对 HFpEF 患者和射血分数降低的心力衰竭(HFrEF)患者死亡率的影响。
我们从 CHART-2 研究中连续纳入了 2688 例窦性节律的 C 期或 D 期 HF 患者(n=10219)。比较了两组患者中 HR 升高的预后影响,根据左心室射血分数<50%(HFrEF)和>50%(HFpEF)定义。Cox 回归分析显示,基线 HR 升高与两组患者的全因死亡率增加相关[HFrEF 中最高三分位(HH)的危险比为 1.77,P=0.008;HFpEF 中 HH 为 1.82,P=0.001]。然而,就死亡模式而言,HR 升高与 HFpEF 中的心血管(CV)死亡相关(HH 2.17,P=0.012),但在 HFrEF 中相关性较弱(HH 1.49,P=0.14):特别是,HFpEF 中 HF 死亡的影响(HH 3.79,P=0.020)与 HFrEF 中 HF 死亡的影响(HH 1.07,P=0.864)不同。相比之下,仅在 HFrEF 患者中观察到基线 HR 对非 CV 死亡的预后影响。β受体阻滞剂治疗与 HFrEF 中的 HF 死亡率降低相关(危险比 0.49,P=0.038),但与 HFpEF 无关(危险比 0.64,P=0.321)。
与 HFrEF 相比,HFpEF 中 HR 升高与 CV 死亡增加相关,尽管两组之间全因死亡率的影响相当。